Table of Contents

1 Study Coverage

• 1.1 Dermatological Drugs Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Dermatological Drugs Market Size Growth Rate by Product
  • 1.4.2 Prescription-Based Drugs
  • 1.4.3 Over-the-Counter Drugs
• 1.5 Market by End User
  • 1.5.1 Global Dermatological Drugs Market Size Growth Rate by End User
  • 1.5.2 Acne
  • 1.5.3 Skin Infections
  • 1.5.4 Psoriasis
  • 1.5.5 Dermatitis Drugs
  • 1.5.6 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Dermatological Drugs Market Size
  • 2.1.1 Global Dermatological Drugs Revenue 2014-2025
  • 2.1.2 Global Dermatological Drugs Sales 2014-2025
• 2.2 Dermatological Drugs Growth Rate by Regions
  • 2.2.1 Global Dermatological Drugs Sales by Regions
  • 2.2.2 Global Dermatological Drugs Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Dermatological Drugs Sales by Manufacturers
  • 3.1.1 Dermatological Drugs Sales by Manufacturers
  • 3.1.2 Dermatological Drugs Sales Market Share by Manufacturers
  • 3.1.3 Global Dermatological Drugs Market Concentration Ratio (CR5 and HHI)
• 3.2 Dermatological Drugs Revenue by Manufacturers
  • 3.2.1 Dermatological Drugs Revenue by Manufacturers (2014-2019)
  • 3.2.2 Dermatological Drugs Revenue Share by Manufacturers (2014-2019)
• 3.3 Dermatological Drugs Price by Manufacturers
• 3.4 Dermatological Drugs Manufacturing Base Distribution, Product Types
  • 3.4.1 Dermatological Drugs Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Dermatological Drugs Product Type
  • 3.4.3 Date of International Manufacturers Enter into Dermatological Drugs Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Dermatological Drugs Sales by Product
• 4.2 Global Dermatological Drugs Revenue by Product
• 4.3 Dermatological Drugs Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Dermatological Drugs Breakdown Data by End User

6 North America

• 6.1 North America Dermatological Drugs by Countries
  • 6.1.1 North America Dermatological Drugs Sales by Countries
  • 6.1.2 North America Dermatological Drugs Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Dermatological Drugs by Product
• 6.3 North America Dermatological Drugs by End User

7 Europe

• 7.1 Europe Dermatological Drugs by Countries
  • 7.1.1 Europe Dermatological Drugs Sales by Countries
  • 7.1.2 Europe Dermatological Drugs Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Dermatological Drugs by Product
• 7.3 Europe Dermatological Drugs by End User

8 Asia Pacific

• 8.1 Asia Pacific Dermatological Drugs by Countries
  • 8.1.1 Asia Pacific Dermatological Drugs Sales by Countries
  • 8.1.2 Asia Pacific Dermatological Drugs Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Dermatological Drugs by Product
• 8.3 Asia Pacific Dermatological Drugs by End User

9 Central & South America

• 9.1 Central & South America Dermatological Drugs by Countries
  • 9.1.1 Central & South America Dermatological Drugs Sales by Countries
  • 9.1.2 Central & South America Dermatological Drugs Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Dermatological Drugs by Product
• 9.3 Central & South America Dermatological Drugs by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Dermatological Drugs by Countries
  • 10.1.1 Middle East and Africa Dermatological Drugs Sales by Countries
  • 10.1.2 Middle East and Africa Dermatological Drugs Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Dermatological Drugs by Product
• 10.3 Middle East and Africa Dermatological Drugs by End User

11 Company Profiles

• 11.1 Bayer
  • 11.1.1 Bayer Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Bayer Dermatological Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Bayer Dermatological Drugs Products Offered
  • 11.1.5 Bayer Recent Development
• 11.2 Johnson & Johnson
  • 11.2.1 Johnson & Johnson Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Johnson & Johnson Dermatological Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Johnson & Johnson Dermatological Drugs Products Offered
  • 11.2.5 Johnson & Johnson Recent Development
• 11.3 Pfizer
  • 11.3.1 Pfizer Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Pfizer Dermatological Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Pfizer Dermatological Drugs Products Offered
  • 11.3.5 Pfizer Recent Development
• 11.4 Novartis
  • 11.4.1 Novartis Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Novartis Dermatological Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Novartis Dermatological Drugs Products Offered
  • 11.4.5 Novartis Recent Development
• 11.5 GlaxoSmithKline
  • 11.5.1 GlaxoSmithKline Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 GlaxoSmithKline Dermatological Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 GlaxoSmithKline Dermatological Drugs Products Offered
  • 11.5.5 GlaxoSmithKline Recent Development
• 11.6 AstraZeneca
  • 11.6.1 AstraZeneca Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 AstraZeneca Dermatological Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 AstraZeneca Dermatological Drugs Products Offered
  • 11.6.5 AstraZeneca Recent Development
• 11.7 Galderma
  • 11.7.1 Galderma Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Galderma Dermatological Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Galderma Dermatological Drugs Products Offered
  • 11.7.5 Galderma Recent Development
• 11.8 Amgen
  • 11.8.1 Amgen Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Amgen Dermatological Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Amgen Dermatological Drugs Products Offered
  • 11.8.5 Amgen Recent Development
• 11.9 AbbVie
  • 11.9.1 AbbVie Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 AbbVie Dermatological Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 AbbVie Dermatological Drugs Products Offered
  • 11.9.5 AbbVie Recent Development
• 11.10 Merck
  • 11.10.1 Merck Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Merck Dermatological Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Merck Dermatological Drugs Products Offered
  • 11.10.5 Merck Recent Development

12 Future Forecast

• 12.1 Dermatological Drugs Market Forecast by Regions
  • 12.1.1 Global Dermatological Drugs Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Dermatological Drugs Revenue Forecast by Regions 2019-2025
• 12.2 Dermatological Drugs Market Forecast by Product
  • 12.2.1 Global Dermatological Drugs Sales Forecast by Product 2019-2025
  • 12.2.2 Global Dermatological Drugs Revenue Forecast by Product 2019-2025
• 12.3 Dermatological Drugs Market Forecast by End User
• 12.4 North America Dermatological Drugs Forecast
• 12.5 Europe Dermatological Drugs Forecast
• 12.6 Asia Pacific Dermatological Drugs Forecast
• 12.7 Central & South America Dermatological Drugs Forecast
• 12.8 Middle East and Africa Dermatological Drugs Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Dermatological Drugs Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

Dermatology is a field of medicine that is engaged in the diagnosis, prevention, and treatment of various skin, nails, hair diseases, pigmentation, acne, wrinkles, psoriasis, and others.
Different techniques are used in dermatology such as topical & systemic medications, laser therapy, radio therapy, photodynamic therapy, vitiligo surgery, dermatological surgery, and others.
The global Dermatological Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Dermatological Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Dermatological Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Dermatological Drugs in these regions.
This research report categorizes the global Dermatological Drugs market by top players/brands, region, type and end user. This report also studies the global Dermatological Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Bayer
Johnson & Johnson
Pfizer
Novartis
GlaxoSmithKline
AstraZeneca
Galderma
Amgen
AbbVie
Merck

Market size by Product
By drug type
Prescription-Based Drugs
Over-the-Counter Drugs
By route of administration
Topical Administration
Oral Administration
Parenteral Administration
By dermatological diseases
Acne
Dermatitis
Psoriasis
Skin Cancer
Rosacea
Alopecia
Others
Market size by End User
Acne
Skin Infections
Psoriasis
Dermatitis Drugs
Other

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Dermatological Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Dermatological Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Dermatological Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Dermatological Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Dermatological Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Dermatological Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.